Hints and tips:
...Geron, the Californian biotech company, is abandoning its pioneering embryonic stem cell work after concluding that the costs and length of further development were too great....
...Only two pharmaceutical companies, Geron and ACT, are at present testing embryonic stem-cell therapies in patients. Others investigating their potential include Cellectis and Pfizer....
...Much research remains at a very early stage, though Geron in the US has already begun clinical trials for spinal cord injury, and the report highlights future areas of expansion with a shift from the use...
...Fetal stem cells are scientifically distinct from the embryonic stem cells being used by Geron, a larger biotech company, for a clinical trial to treat spinal injury in the US....
...Geron, based in California, stole a march on its competitors on Monday when it said it had enrolled the first person for a trial in Atlanta, Georgia, to treat patients with spinal cord injuries....
...Last year the FDA put Geron’s trial “on clinical hold” because of safety concerns raised by one of the animal studies used to support the application....
...Biotechnology company Geron jumped 17.3 per cent to $5.63 after it said that the Food and Drug Administration had lifted its hold on an early-stage trial of its embryonic stem cell-based therapy....
...Within three days of the warning that the oil sheen was heading for Florida’s panhandle beaches, Geronimo’s Outpost sold out of one particular item....
...David Earp, senior vice-president of business development at Geron, said: “Geron is intensely focused on developing human embryonic stem cell-based therapies and the expertise we have developed in scaleable...
...Geron, a Californian biotech company, plans to inject nerve cells derived from embryonic stem cells into patients paralysed by recent spinal cord injury....
...Mr Okarma said Geron could achieve important economies of scale designed to ensure that the price of the new treatment would be “reasonable”....
...Later this year, the agency expects to receive applications to test such treatments on patients; the pioneer is likely to be Geron, a Californian company aiming to restore limb movement in people paralysed...
...But the FDA is proceeding with caution and this month put the clinical trial application – from Geron, the Californian biotech company – to treat spinal injuries “on hold”....
...Using a new culture technique, the UW/Geron researchers turned 90 per cent of their stem cells into cardiomyocytes....
...Geron slid 3.8 per cent to $7.15 after the US Patent Office ruled out three patents on human embryonic research held by the company....
...Geron slid 7.4 per cent to $8.65 after the biopharmaceutical company sold new stock for institutional investors at $8 per share....
...Geron shares were up 3.3 per cent to $8.66. Housing agency Fannie Mae was up 2.9 per cent at $61.65 and Freddie Mac was 2 per cent stronger at $71.23....
International Edition